Heparin Market

Global Heparin Market is valued at US$ 7.32 Billion in 2022 and expected to reach US$ 11.37 Billion by 2029 with a CAGR of 6.5% over the forecast period.

Global Heparin Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Increasing prevalence of blood clotting disorders, growing geriatric population and rising demand for anticoagulant drugs are major factors anticipated to drive the growth of the Global Heparin Market within the forecast period.

Scope of Global Heparin Market Report–

Heparin is a naturally occurring anticoagulant (blood thinner) that is produced by certain cells in the body, such as mast cells and basophils. It works by inhibiting the formation of blood clots, which can block blood vessels and cause serious medical conditions such as deep vein thrombosis (DVT) and pulmonary embolism. Heparin is commonly used in medicine as a medication to prevent blood clots in people who are at high risk of developing them, such as those who have undergone surgery, those with certain types of heart disease, and those with a history of blood clots. It is also used to treat existing blood clots. Heparin is usually given by injection, either under the skin (subcutaneously) or into a vein (intravenously). It is considered a high-risk medication and must be carefully dosed and monitored to prevent bleeding complications.

The Covid-19 pandemic had a significant impact on global heparin market. The pandemic initially caused disruptions in the supply chain, but the demand for heparin increased due to its potential benefits in treating Covid-19 patients. This led to growth in the market for heparin during the early stages of the pandemic. For instance; as per the  news published on January 20^th, 2022; in the British Journal of Clinical Pharmacology Clinical trial shown common drug heparin can be used to improve Covid-19 symptoms, that used heparin to treat 98 patients diagnosed with Covid-19. The study's authors suggest that heparin could be a useful treatment option for Covid-19 patients, especially those with underlying medical conditions that increase their risk of blood clots.

The global heparin market is segmented on the basis of type, application, source,  region and country level. On the basis of type, the global heparin market is segmented into heparin market is segmented by product into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). On the basis of application, the marker is segmented into deep vein thrombosis (DVT), atrial fibrillation and heart attack, coronary artery disease, and others. On the basis of source, the global heparin market is segmented into, bovine and porcine.

The regions covered in global heparin market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global heparin market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

Key Players for Global Heparin Market Report-

Some of the key players for global heparin market are -

• Pfizer Inc.
• GLAND PHARMA
• Novartis AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Leo Pharma A/S
• Baxter International Inc.
• Aspen Pharmacare Holdings Limited
• B Braun Melsungen AG
• Reddy's Laboratories
• Hebei Changshan Biochemical Pharmaceutical
• Leo Pharma AS
• Opocrin SpA
• others

Global Heparin Market Segmentation-

By Type:-

• Unfractionated Heparin
• Low Molecular Weight Heparin (LMWH)
• Ultra-Low Molecular Weight Heparin (ULMWH)

By Application:-

• Deep Vein Thrombosis (DVT)
• Atrial Fibrillation and Heart Attack
• Coronary Artery Disease
• Others

By Source:-

• Bovine
• Porcine

By Regional & Country Analysis:

• North America

• U.S.
• Mexico
• Canada

• Europe

• UK
• France
• Germany
• Italy

• The Asia Pacific

• China
• Japan
• India
• Southeast Asia

• South America

• Brazil,
• Argentina
• Columbia

• The Middle East and Africa

• GCC
• Africa
• Rest of the Middle East and Africa

Global Heparin Market Dynamics-

Increasing prevalence of blood clotting disorders, growing geriatric population, rising demand for anticoagulant drugs are major factors anticipated to drive the growth of the global heparin market for the forecast period.

One of the major factors driving the global heparin market is the increasing prevalence of blood clotting disorders. The global heparin market is primarily driven by the increasing prevalence of blood clotting disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. These conditions are common among the aging population, and their incidence is rising due to lifestyle changes such as sedentary behavior, obesity, and smoking.

For instance; as per the data published by the Centers for Disease Control and Prevention in 2018 deep vein thrombosis and pulmonary embolism harm around 900,000 people in the U.S. each year. Hence, as heparin is a commonly used blood-thinning medication for preventing and treating these conditions, the growing prevalence of blood clotting disorders is expected to drive the demand for heparin in the coming years.

In addition, growing geriatric population is another significant factor driving the growth of the global heparin market. As people age, they become more prone to blood clotting disorders such as deep vein thrombosis and pulmonary embolism. The geriatric population is also more likely to have underlying medical conditions such as cancer, heart disease, and diabetes that increase the risk of blood clots.

For instance; according to the United Nations, the global population aged 65 years and above is projected to reach 1.5 billion by 2050, nearly triple the number in 2019. This demographic shift is expected to lead to an increase in the prevalence of age-related medical conditions, which, in turn, is expected to drive the demand for heparin and other anticoagulant drugs.

Moreover, the rising demand for anticoagulant drugs is also supplementing the market growth.  The global market for anticoagulant drugs is expected to grow significantly in the coming years, driven by the increasing incidence of cardiovascular diseases, stroke, and cancer. Heparin is one of the most commonly used anticoagulant drugs, and the growing demand for these drugs and its subsequent launches are expected to drive the growth of the global heparin market.

For instance; in  January 2022, Optimvia Pharmaceuticals announced that it developed a new, more efficient method for synthesizing heparin. The company claims that this method is much more efficient and cost-effective than traditional extraction methods, allowing for the production of large quantities of heparin at a reasonable price.

However, the high cost of thrombectomy devices, and the high risk of infection are expected to hamper  the market growth. In spite of that, increasing cases of coronary artery disease may provide more opportunities for the further growth of the market.

Global Heparin Market Regional Analysis-

North America is expected to dominate the global heparin market due to increasing burden of chronic diseases, presence of major market players and rising research and development activities in this field in this region. The increasing burden of chronic diseases such as cardiovascular diseases, cancer, and diabetes has led to a growing demand for anticoagulant medications such as heparin.

For instance; as per the American Heart Association, cardiovascular disease is the leading cause of death in the United States, with approximately 1 in 4 deaths attributed to the condition. This high prevalence of chronic diseases has created a significant market for heparin and other anticoagulant drugs in North America.

In addition, North America is home to several major players in the heparin market, including Techdow USA ,Pfizer, Sanofi, and Fresenius Kabi. These companies have a strong presence in the region and are constantly investing in research and development to improve their products and stay competitive in the market. Moreover, North America is also home to many leading academic institutions and research organizations that are actively engaged in heparin-related research and product launches which boosting the market growth in this region.

For example; in February 2022, Techdow USA Inc. announced the launch of its Heparin Sodium Injection product in the United States market. The product is a generic version of the blood thinner heparin, which is used to prevent and treat blood clots.

Asia Pacific is growing at significant rate for the global heparin market due to  adoption of technologically advanced products, rising government initiatives and growing number of cardiovascular diseases. Governments in the Asia-Pacific region are taking initiatives to promote the use of heparin and other anticoagulant drugs.

In addition, the high prevalence of chronic diseases such as cardiovascular disease, diabetes, and cancer is also driving demand for heparin and other anticoagulant medications. For instance; as per the National Institute of Health,  India has one of the highest burdens of cardiovascular disease (CVD) worldwide. The annual number of deaths from CVD in India is projected to rise from 2.26 million to 4.77 million in 2020.

News-

Techdow USA Announced Launch of Heparin Sodium Injection, USP in the United States

On February 8^th, 2022; Techdow USA, a subsidiary of the global pharmaceutical company Techdow Group, announced the launch of Heparin Sodium Injection, USP in the United States. Heparin Sodium Injection is a blood-thinning medication that is used to prevent and treat blood clots in patients with various medical conditions, including deep vein thrombosis and pulmonary embolism. The medication is also used during certain medical procedures, such as dialysis and heart surgery. The launch of Heparin Sodium Injection in the US will provide patients with another option for managing their medical conditions and will increase competition in the heparin market.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 7.32 Billion
Base year considered	2021
Forecast Period CAGR %:	6.5%
Market Size Expected in 2029:	USD 11.37 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Pfizer, Inc., GLAND PHARMA,  Novartis AG,  Sanofi S.A., GlaxoSmithKline plc, Leo Pharma A/S, and Baxter International Inc. Aspen Pharmacare Holdings Limited, B Braun Melsungen AG, Baxter International Inc., Dr. Reddy's Laboratories, Hebei Changshan Biochemical Pharmaceutical, Leo Pharma AS, Opocrin SpA, and others
Segments Covered	By Type, By Source, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa